Literature DB >> 25013524

Isolated system towards a successful radiotherapy treatment.

Emad Moawad1.   

Abstract

PURPOSE: Establishment of the specifications and standards for successful radiotherapy treatments through identifying three objectives: administering the appropriate low-waste dose, developing dose-delivery skills and monitoring an earlier response to therapy.
METHODS: The appropriate low-waste dose is administered via the work-energy principle, considering the interaction between the drug and the tumor as an isolated system. Then, chelated with any compound that could form a lipid-soluble complex with the radioactive metal ions, it is injected directly into the tumor via a multihole needle to improve the distribution of the injectate solution. This can be detected by monitoring the tumor response through newer imaging techniques that combine single photon emission computed tomography (SPECT) with computed tomography (CT), or positron emission tomography (PET) with CT, so that nonresponding tumors can be identified early to modify the administered dose.
RESULTS: The accuracy of estimating the initial effective radioactive dose depends on the equivalence of the growth energy of the tumor estimated from the CT scan and the decay energy of the effective radioactive dose. Besides earlier or more accurate assessment of the tumor response by PET with the glucose analogue (18)F-fluoro-2-deoxyglucose ((18)F-FDG), this contributes to the most safe and low-cost successful treatment. This approach assessed the therapeutic significance of lipid-soluble compounds with the radioactive metal ions in protecting system isolation, which plays a major role in targeted tumor therapy.
CONCLUSION: Treatment success shows that the three identified objectives are completely dependent objectives. It should also be taken into consideration that radionuclide decay-generated Auger electrons may be more effective in very small tumors to avoid a cross dose.

Entities:  

Keywords:  Emad; Growth energy; Isolated radiotherapy; Work-energy principle

Year:  2010        PMID: 25013524      PMCID: PMC4079774          DOI: 10.1007/s13139-010-0029-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  30 in total

1.  Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes.

Authors:  Pablo R Castello; Pamela S David; Travis McClure; Zachary Crook; Robert O Poyton
Journal:  Cell Metab       Date:  2006-04       Impact factor: 27.287

2.  Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume.

Authors:  Goran Torlakovic; Vaneeta K Grover; Emina Torlakovic
Journal:  Croat Med J       Date:  2005-06       Impact factor: 1.351

Review 3.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

4.  Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

Authors:  E C Barendswaard; J L Humm; J A O'Donoghue; G Sgouros; R D Finn; A M Scott; S M Larson; S Welt
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

Review 5.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

Review 6.  Hypoxia-driven selection of the metastatic phenotype.

Authors:  Richard Sullivan; Charles H Graham
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

7.  Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.

Authors:  Cecilia Hindorf; Ola Lindén; Lars Stenberg; Jan Tennvall; Sven-Erik Strand
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

8.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

Review 9.  Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.

Authors:  Wolfgang A Weber; Johannes Czernin; Michael E Phelps; Harvey R Herschman
Journal:  Nat Clin Pract Oncol       Date:  2008-01

10.  Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.

Authors:  P L Roberson; D J Buchsbaum
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

View more
  10 in total

1.  Clinical and pathological staging of the cancer at the nanoscale.

Authors:  Emad Y Moawad
Journal:  Cancer Nanotechnol       Date:  2012-07-22

2.  Administering the Optimum Dose of l-Arginine in Regional Tumor Therapy.

Authors:  Emad Y Moawad
Journal:  Indian J Clin Biochem       Date:  2013-09-15

3.  Induction of multiple sclerosis and response to tyrosine kinase inhibitors.

Authors:  Emad Y Moawad
Journal:  Indian J Clin Biochem       Date:  2013-09-28

4.  Radiotherapy and risks of tumor regrowth or inducing second cancer.

Authors:  Emad Y Moawad
Journal:  Cancer Nanotechnol       Date:  2011-08-18

5.  Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).

Authors:  Emad Y Moawad
Journal:  J Gastrointest Cancer       Date:  2015-09

6.  Optimizing bioethanol production by regulating yeast growth energy.

Authors:  Emad Y Moawad
Journal:  Syst Synth Biol       Date:  2012-11-10

7.  Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.

Authors:  Emad Y Moawad
Journal:  J Gastrointest Cancer       Date:  2015-12

8.  Identifying the optimal dose of ritonavir in the treatment of malignancies.

Authors:  Emad Y Moawad
Journal:  Metab Brain Dis       Date:  2013-11-19       Impact factor: 3.584

9.  Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer.

Authors:  Yirui Guo; Dingyao Gao; Yinfei Chen; Yu Zhang; Liping Chen; Yong Mao; Chunjing Yu; Ling Qiu; Jianguo Lin
Journal:  ACS Omega       Date:  2021-03-17

10.  Data to establish the optimal standard regimen and predicting the response to docetaxel therapy.

Authors:  Emad Y Moawad
Journal:  Data Brief       Date:  2015-10-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.